Literature DB >> 22000560

Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.

A Broughton1, J-P Cosyns, M Jadoul.   

Abstract

We report the case of a 53-year-old woman treated for 8 years with Betaferon® (interferon-β-1b), who developed mild renal failure with hypertension, proteinuria and glomerular hematuria. Kidney biopsy was consistent with thrombotic microangiopathy (TMA). Considering the strong evidence of interferon-α causing TMA and the numerous immunomodulatory activities shared by INF-α and -β, we incriminated Betaferon as the etiological agent of TMA in our patient. To our knowledge, it is the first time such an association has been published.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000560     DOI: 10.5414/cn106523

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  12 in total

1.  Hemolytic uremic syndrome: an unusual complication of interferon-β treatment in a MS patient.

Authors:  Elodie Nerrant; Mahmoud Charif; Anne-Sophie Ramay; Hélène Perrochia; Laure Patrier; Nicolas Menjot de Champfleur; Dimitri Renard; Pierre Labauge
Journal:  J Neurol       Date:  2013-05-25       Impact factor: 4.849

2.  Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.

Authors:  Corentin Orvain; Jean-François Augusto; Virginie Besson; Guillaume Marc; Paul Coppo; Jean-François Subra; Johnny Sayegh
Journal:  Int Urol Nephrol       Date:  2013-02-24       Impact factor: 2.370

3.  Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report.

Authors:  Haruomi Nishio; Tatsuo Tsukamoto; Takeshi Matsubara; Yoichiro Okada; Ryosuke Takahashi; Motoko Yanagita
Journal:  CEN Case Rep       Date:  2016-06-20

4.  Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients.

Authors:  Tatiana Koudriavtseva; Domenico Plantone; Rosaria Renna; Chiara Mandoj; Diana Giannarelli; Caterina Mainero
Journal:  Neurol Sci       Date:  2015-07-26       Impact factor: 3.307

5.  Thrombotic microangiopathy associated with use of interferon-beta.

Authors:  Teresa Olea; Raquel Díaz-Mancebo; Maria-Luz Picazo; Jorge Martínez-Ara; Angel Robles; Rafael Selgas
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-06-15

6.  Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a.

Authors:  Ali-Frédéric Ben-Amor; Anton Trochanov; Tanya Z Fischer
Journal:  Adv Ther       Date:  2015-05-20       Impact factor: 3.845

7.  Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.

Authors:  Julien Mahe; Aurélie Meurette; Anne Moreau; Caroline Vercel; Pascale Jolliet
Journal:  Drug Des Devel Ther       Date:  2013-08-07       Impact factor: 4.162

8.  Thrombotic Microangiopathy in Interferon-beta-Treated Multiple Sclerosis Patient.

Authors:  Masoud Mohammad Malekzadeh; Reza Alizadeh; Ziba Aghsaeifard; Mohammad Ali Sahraian
Journal:  Clin Case Rep       Date:  2020-03-30

9.  Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis.

Authors:  Seyed Mohammad Baghbanian; Abdorreza Naser Moghadasi
Journal:  Iran J Neurol       Date:  2018-04-04

10.  Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab.

Authors:  Marco Allinovi; Calogero Lino Cirami; Leonardo Caroti; Giulia Antognoli; Silvia Farsetti; Maria Pia Amato; Enrico Eugenio Minetti
Journal:  Clin Kidney J       Date:  2017-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.